Antidepressant efficacy and side effect burden: an updated guide for clinicians

Tatum Kutzer DO, Michelle Dick MD, Trevor Scudamore MD, Mark Wiener MD, Thomas Schwartz MD

Article Type

Review

Published

This article serves to provide clinicians with updated information about novel antidepressant medications, augmentation strategies with atypical antipsychotics, over-the-counter medications, as well as nonpharmaceutical treatments that should be considered when treating each individual patient who remains symptomatic despite treatment efforts.

Read more

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder

James M Martinez, Margaret B Ferguson, Beth A Pangallo, Tina M Oakes, JonDavid Sparks, Mary Anne Dellva, Qi Zhang, Peng Liu, Mark Bangs, Jonna Ahl, Celine Goldberger

Article Type

Original Research

Published

This analysis confirms that the tolerability and safety profile of edivoxetine as adjunctive treatment to SSRI antidepressants was consistent with its norepinephrine reuptake inhibitor mechanism of action, and was comparable with edivoxetine monotherapy treatment in patients with major depressive disorder.

Read more

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary

Susan G Ball, Durisala Desaiah, Qi Zhang, Michael E Thase, David G S Perahia

Article Type

Review

Published

Major depressive disorder (MDD) is a significant public health concern and challenges health care providers to intervene with appropriate treatment. This review provides evidence that duloxetine 60 mg QD is effective for the treatment of adult patients with MDD in the short- and long-term phases of treatment. Duloxetine 60 mg QD also represents a viable choice of treatment for those patients with painful physical symptoms associated with MDD.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.